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OBJECTIVE
Efficacy and safety of the glucagon-like peptide 1 (GLP-1) analog oral semaglutide
and the sodium–glucose cotransporter 2 inhibitor empagliflozin were compared in
patients with type 2 diabetes uncontrolled on metformin.
RESEARCH DESIGN AND METHODS
Patients were randomized to once-daily open-label treatment with oral semaglu-
tide 14 mg (n5 412) or empagliflozin 25 mg (n5 410) in a 52-week trial. Key end
points were change from baseline to week 26 in HbA1c (primary) and body weight
(confirmatory secondary). Two estimands addressed efficacy-related questions:
treatment policy (regardless of trial product discontinuation or rescue medication)
and trial product (on trial product without rescue medication) in all randomized
patients.
RESULTS
Four hundred (97.1%) patients in the oral semaglutide group and 387 (94.4%) in the
empagliflozin group completed the trial. Oral semaglutide provided superior
reductions in HbA1c versus empagliflozin at week 26 (treatment policy –1.3% vs.
–0.9% [–14 vs. –9 mmol/mol], estimated treatment difference [ETD] –0.4% [95% CI
–0.6, –0.3] [–5 mmol/mol (–6, –3)]; P < 0.0001). The treatment difference in HbA1c
significantly favored oral semaglutide at week 26 for the trial product estimand
(–1.4%vs.–0.9%[–15vs.–9mmol/mol], ETD–0.5%[95%CI–0.7,–0.4] [–6mmol/mol
(–7, –5)]; P < 0.0001) and at week 52 for both estimands (P < 0.0001). Superior
weight loss was not confirmed at week 26 (treatment policy), but oral semaglu-
tide was significantly better than empagliflozin at week 52 (trial product 24.7 vs.
23.8 kg; P 5 0.0114). Gastrointestinal adverse events were more common
with oral semaglutide.
CONCLUSIONS
Oral semaglutide was superior to empagliflozin in reducing HbA1c but not body
weight at 26 weeks in patients with type 2 diabetes uncontrolled onmetformin. At
week52,HbA1c andbodyweight (trial product estimand)were significantly reduced
versus empagliflozin. Oral semaglutide was well tolerated within the established
safety profile of GLP-1 receptor agonists.
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Many patients with type 2 diabetes fail to
achieve or maintain adequate blood glu-
cose control when treated with metformin
monotherapy. Injectable glucagon-like
peptide 1 receptor agonists (GLP-1RAs)
and oral sodium–glucose cotransporter 2
(SGLT-2) inhibitors are recommended as
second-line therapy because of their abil-
ity to lower glucose without increasing
hypoglycemia risk, weight loss effect, and
associated cardiovascular benefits (1,2).
Semaglutide is a human GLP-1 analog
currently available as a once-weekly in-
jection associated with reduced glycated
hemoglobin (HbA1c), weight loss, and
fewer cardiovascular events in type 2 di-
abetes (3–9). Oral semaglutide is cofor-
mulated in a tablet with the absorption
enhancersodiumN-(8-[2-hydroxylbenzoyl]
amino) caprylate, which facilitates
semaglutide absorption across the gastric
mucosa (10). Oral semaglutide has dem-
onstrated significantly greater reductions
in HbA1c and body weight compared with
placebo in patients with type 2 diabetes
uncontrolled with diet and exercise or oral
antidiabetic medication, including in pa-
tients with moderate renal impairment
(11–14). Significantly greater reductions
in HbA1c and body weight have also been
shown with oral semaglutide, given as 7 or
14 mg/day or flexibly dosed, compared
with sitagliptin in patients uncontrolled
with oral antidiabetic drugs (15,16). Oral
semaglutide also resulted in a noninferior
reduction in HbA1c and superior weight
loss versus liraglutide in patients on met-
formin with or without an SGLT-2 inhibitor
(13). Cardiovascular safety has been con-
firmed, with an indication of benefit, by
a nonsignificant 21% risk reduction in
major adverse cardiovascular events
versus placebo (17).
Empagliflozin is a widely used oral
SGLT-2 inhibitor shown to improve gly-
cemic control and body weight (18–22)
and associated with a reduced risk of
cardiovascular and all-cause mortality in
patients at high cardiovascular risk (23).
The present phase 3a trial, PIONEER 2,
is the first direct comparison of oral
semaglutide with an SGLT-2 inhibitor,
empagliflozin, in type 2 diabetes uncon-
trolled with metformin monotherapy.
RESEARCH DESIGN AND METHODS
Trial Design
This randomized, open-label, multina-
tional 52-week trial was conducted at
108 sites in 12 countries (Argentina,
Brazil, Croatia, Greece, Hungary, Italy,
Poland, Russia, Serbia, Spain, Thailand,
U.S.). Patients were randomized (1:1) to
once-daily oral semaglutide 14 mg or
empagliflozin 25 mg for 52 weeks using
an interactive web response system
with a further 5 weeks of follow-up
(Supplementary Fig. 1). An open-label
trial design was used because manufac-
ture of placebo tablets resembling em-
pagliflozin was not feasible within a
reasonable time frame. Oral semaglutide
was initiated at 3 mg once daily, esca-
lated to 7 mg at week 4 and 14 mg after
week 8. Because food impairs absorption
of oral semaglutide, patients were in-
structed to administer oral semaglutide
in themorning in a fasted statewith up to
120 mL of water at least 30 min before
breakfast and any other oral medication.
Empagliflozin was initiated at 10 mg once
daily in the morning and escalated to
25 mg at week 8.
Additional antidiabetic medication
was available for patients with persistent
or unacceptable hyperglycemia on trial
product and for patients who prema-
turely discontinued trial product and
remained in the trial. Additional antidi-
abetic medication was defined as that
initiated (or intensification of existing
antidiabetic background medication
by a dose increase of .20%) during
the planned treatment period (i.e.,
from randomization to the planned
end-of-treatment visit) either as add-on
to trial product or initiated after pre-
mature discontinuation of trial product.
The subset of additional antidiabetic
medication (or intensification of existing
antidiabetic background medication)
used as add-on to trial product is defined
as rescue medication. Short-term use
(#21 days) of antidiabetic medication
(e.g., in connection with intercurrent
illness) was not considered as additional
antidiabetic medication (including res-
cue medication).
Rescue criteria were fasting plasma
glucose .260 mg/dL (14.4 mmol/L)
from week 8 to 13, .240 mg/dL (13.3
mmol/L) from week 14 to 25, and .200
mg/dL (11.1 mmol/L) (or HbA1c .8.5%
[69.4 mmol/mol]) from week 26 onward.
Rescue medication was prescribed at the
investigator’s discretion (excluding GLP-
1RAs, dipeptidyl peptidase 4 inhibitors,
and amylin analogs in theoral semaglutide
arm and SGLT-2 inhibitors in the empagli-
flozin arm). Patients who prematurely
discontinued trial product remained in
the trial and could receive any other an-
tidiabetic medications at the investigator’s
discretion (excluding GLP-1RAs in the oral
semaglutide arm before completion of the
follow-up visit 5 weeks after the last date
on trial product).
Two different questions related to
the efficacy objectives were addressed
through the definition of two estimands:
treatment policy and trial product. Both
estimands were defined based on inter-
actions with regulatory agencies. The
treatment policy estimand evaluates the
treatment effect for all randomized pa-
tients, regardless of trial product discon-
tinuation oruse of rescuemedication. This
estimand reflects the intention-to-treat
principle as defined in International Coun-
cil on Harmonization (ICH) E9 (24). The
estimand reflects the effect of initiating
treatment with oral semaglutide com-
pared with initiating treatment with em-
pagliflozin, both potentially followed by
either discontinuation of trial product
and/or addition of or switch to another
glucose-lowering drug.
The trial product estimand evaluates
the treatment effect for all randomized
patients under the assumption that all
patients remained on trial product for the
entire planned duration of the trial and
did not use rescue medication. This es-
timand aims at reflecting the effect of
oral semaglutide compared with empa-
gliflozin without the confounding effect
of rescuemedication. The statistical anal-
ysis that was applied to estimate this
estimand is similar to howmanyphase 3a
diabetes trials have been evaluated,
and results from such analyses are
currently included in many product
labels (prescribing information, U.S.,
and summary of product characteristics,
European Union) for glucose-lowering
drugs (e.g., Ozempic summary of product
characteristics).
Trial product discontinuation and initia-
tion of rescue medication are accounted
for by the treatment policy strategy for the
treatment policy estimand and by the
hypothetical strategy for the trial product
estimand as defined in draft ICH E9 (R1)
(25). Further details on the use of estimands
in this trial are provided in Supplementary
Data, Estimands, with additional back-
ground provided by Aroda et al. (26).
The trial protocol was approved by
all relevant institutional review boards/
independent ethics committees, and the
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trial was conducted in accordancewith ICH
Good Clinical Practice guidelines and the
Declaration of Helsinki. All patients pro-
vided written informed consent before
any trial-related activity.
Patients
Eligible patients were adults with type 2
diabetes and an HbA1c of 7.0–10.5%
(53–91 mmol/mol) receiving a stable
dose of metformin ($1,500 mg or max-
imum tolerated). Key exclusion criteria
(see Supplementary Table 1 for full list)
were any medication for diabetes or
obesity within the previous 90 days
other than metformin or short-term
(#14 days) insulin, renal impairment
with an estimated glomerular filtration
rate ,60 mL/min/1.73 m2, proliferative
retinopathy or maculopathy requiring
acute treatment verified by fundus pho-
tography or dilated fundoscopy, and
history of pancreatitis.
Trial End Points
The primary end point was change in
HbA1c from baseline to week 26. The
confirmatory secondary end point was
change in bodyweight (kg) from baseline
to week 26.
Secondary end points included changes
frombaseline toweek52 inHbA1c andbody
weight (kg) and changes from baseline to
weeks 26 and 52 in fasting plasma glucose,
self-measured blood glucose (SMBG)
profile (7-point profile andmean postpran-
dial increment over all meals), fasting
C-peptide, fasting insulin, fastingproinsulin,
fasting glucagon, HOMA of insulin resis-
tance (HOMA-IR), HOMA of b-cell function
(HOMA-B), C-reactive protein, bodyweight
(%), BMI, waist circumference, and fasting
lipid profile. Other secondary end points
were the proportion of patients achiev-
ing HbA1c ,7% (53 mmol/mol) or#6.5%
(48 mmol/mol); weight loss of $5% or
$10%; composite end point of HbA1c,7%
(53 mmol/mol) without severe or symp-
tomatic hypoglycemia (blood glucose
,56 mg/dL [,3.1 mmol/L]) and no
weight gain; composite end point of an
absolute reduction in HbA1c of $1.0%
(10.9 mmol/mol) and body weight loss
of$3% (weeks 26 and 52); and changes
from baseline to weeks 26 and 52 in
the patient-reported outcomes, Short
Form (SF) 36v2 Health Survey (Acute
Version) (27) and Control of Eating Ques-
tionnaire (28). Further end points are
listed in the Estimands section and the
protocol that are included as part of
the Supplementary Data.
Safety end points included the number
of treatment-emergent adverse events,
incidence of American Diabetes Associa-
tion (ADA)–classified (29) severe or con-
firmed symptomatic hypoglycemic
episodes (blood glucose ,56 mg/dL
[,3.1 mmol/L]), and changes from
baseline in heart rate, blood pressure,
and other clinical and laboratory assess-
ments. An independent external event
adjudication committee (EAC) per-
formed masked validation of predefined
adverse events, including deaths, selected
cardiovascular events, acute pancreatitis,
malignant neoplasms, acute kidney injury,
and lactic acidosis.
Statistical Analysis
The primary end point of change from
baseline to week 26 in HbA1c was tested
for both noninferiority and superiority of
oral semaglutide versus empagliflozin, with
a sample size calculation to ensure a power
of at least 90% for testing superiority. The
confirmatory secondaryendpointof change
from baseline to week 26 in body weight
was tested for superiority of oral semaglu-
tide versus empagliflozin. The confirmation
of efficacy of oral semaglutide on change
in HbA1c and body weight from baseline
to week 26 was based on a weighted
Bonferroni closed testing strategy (30) to
control the overall type I error for the
hypotheses evaluated by the treatment
policy estimand (Supplementary Fig. 2).
Because of the potential for type I errors
as a result of multiple comparisons, find-
ings for analyses of additional secondary
end points should be interpreted as
exploratory.
The treatment policy estimand was es-
timated by a pattern-mixture model using
multiple imputation to handle missing
week 26 data for both confirmatory end
points. Data collected at week 26, irre-
spective of premature discontinuation of
trial product or initiation of rescue med-
ication, were included in the statistical
analysis. Imputation was done within
groups defined by trial product and treat-
ment status at week 26. Both the impu-
tation and the analysis were based
on ANCOVAmodels. The results were com-
bined by use of Rubin’s rule (31). Before
testing for noninferiority, a value of 0.4%
(the noninferiority margin) was added to
imputed values at week 26 for the oral
semaglutide treatment arm only (32).
The trial product estimand was estimated
by a mixed model for repeated measure-
ments that used data collected before
premature trial product discontinuation
or initiation of rescue medication from
all randomized patients.
Further details on the statistical anal-
yses can be found in Supplementary Fig.
2. All analyses were performed using
SAS 9.4M2 statistical software.
Data Availability
Data will be shared with bona fide re-
searchers submitting a research proposal
approved by the independent review
board. Access request proposals can be
found at http://novonordisk-trials.com.
Data will bemade available after research
completion, approval of the product, and
product use in the European Union and
U.S. Individual participant data will be
shared in data sets in a deidentified/




A total of 1,122 patients were screened,
with 822 randomized to oral semaglutide
14mgoncedaily (n5412)orempagliflozin
25 mg once daily (n5 410). Four hundred
(97.1%) patients in the oral semaglutide
group and387 (94.4%) in the empagliflozin
group completed the trial (Supple-
mentary Fig. 3). Baseline characteristics
were well balanced between treatment
groups (Table 1). Patients, of whom half
(49.5%) were female, had a mean age
of 58 years, baseline HbA1c of 8.1%
(65 mmol/mol), fasting plasma glucose
of 173 mg/dL (9.6 mmol/L), average
duration of diabetes of 7.4 years, and
mean body weight of 91.6 kg.
Use of additional antidiabetic medica-
tion and rescue medication is shown in
Supplementary Table 2. Through to week
26, 17 (4.1%) patients initiated addi-
tional antidiabetic medication in the oral
semaglutide group; in 8 (1.9%) of these
patients, it was rescue medication. In the
empagliflozin group, 13 (3.2%) patients ini-
tiated additional antidiabetic medication
through to week 26, with this being
rescue medication in 5 (1.2%). Through
toweek 52, 52 (12.7%) patients initiated
additional antidiabetic medication in
the oral semaglutide group; in 31 (7.5%)
of these patients, it was rescue medi-
cation. In the empagliflozin group, 56
(13.7%) patients initiated additional
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antidiabetic medication, with this being
rescue medication in 44 (10.7%). Sulfo-
nylureas were the most commonly used
additional antidiabetic and rescue med-
ication. Disposition of patients through-
out the trial is shown in Supplementary
Fig 4.
Glycemic Control
Oral semaglutide 14 mg provided a su-
perior reduction in HbA1c compared with
empagliflozin 25 mg at week 26 when
evaluated by the treatment policy esti-
mand (regardless of rescue medication
use or trial product discontinuation)
(–1.3% vs. –0.9% [–14 vs. –9 mmol/mol];
estimated treatment difference [ETD]
–0.4% [95% CI –0.6, –0.3] [–5 mmol/
mol (–6, –3)]; P , 0.0001 for noninfe-
riority and superiority) (Fig. 1). Results
from sensitivity analyses supported
the results of the confirmatory analysis
(Supplementary Fig. 5). When evalu-
ated by the trial product estimand (on
trial product and without the use of
rescue medication), the reduction in
HbA1c was significantly greater with
oral semaglutide at week 26 (–1.4%
vs. –0.9% [–15 vs. –9 mmol/mol], ETD
–0.5% [–0.7, –0.4] [–6 mmol/mol (–7,
–5)]; P , 0.0001) (Fig. 1). Significantly
greater reductions in HbA1c with oral
semaglutide compared with empagli-
flozin were also observed at week 52
(both estimands) (Fig. 1). More patients
achieved the predefined HbA1c targets
with oral semaglutide than with empa-
gliflozin, and the odds of doing so were
significantly greater at weeks 26 and 52
(both estimands, all P , 0.0001) (Fig. 1
and Table 2).
Fasting plasma glucose was reduced
with both treatments, with no significant
difference between groups (Table 2
and Supplementary Fig. 6). Oral sema-
glutide resulted in significantly greater
reductions in mean 7-point SMBG
profiles compared with empagliflozin at
both weeks 26 and 52 (Table 2 and
Supplementary Fig. 6) and significantly
reduced mean postprandial increments,
as averaged for all meals (excluding
the treatment policy estimand evalua-
tion at week 26) (Table 2).
Body Weight
Superiority of body weight reduction at
week 26 with oral semaglutide over em-
pagliflozin was not confirmed (treatment
policy estimand 23.8 vs. 23.7 kg;
ETD 20.1 kg [95% CI 20.7, 0.5];
P5 0.7593). Results from sensitivity anal-
yses supported the results of the con-
firmatory analysis (Supplementary Fig.
5). There was no difference between
treatments using the trial product esti-
mand (24.2 vs. 23.8 kg; ETD 20.4 kg
[21.0, 0.1]; P 5 0.1358) (Fig. 1). A
significantly greater reduction in body
weight was achieved with oral semaglu-
tide versus empagliflozin at week 52
when evaluated by the trial product esti-
mand (24.7 vs. 23.8 kg; ETD 20.9 kg
[21.6, 20.2]; P 5 0.0114) but not
the treatment policy estimand (23.8
vs. 23.6 kg; ETD 20.2 kg [20.9, 0.5];
P 5 0.6231). Proportions of patients
achieving $5% or $10% weight loss
are shown in Fig. 1 and Table 2, respec-
tively. Reductions in waist circumference
were significantly greater with oral sem-
aglutide than with empagliflozin at week
26 (both estimands) and at week 52 (trial
product estimand) (Table 2).
Other Outcomes
More patients achieved the two compos-
ite end points (HbA1c,7% [53mmol/mol]
without severe or symptomatic hypo-
glycemia and no weight gain and an ab-
solute reduction in HbA1c of $1.0%
[10.9 mmol/mol] and body weight loss
of $3%) with oral semaglutide versus
empagliflozin, and the odds of doing so
were significantly greater at both weeks
26 and 52 (Table 2). Reduction in C-reactive
protein was significantly greater with
oral semaglutide versus empagliflozin
(Table 2). Other secondary end points are
presented in Table 2 and Supplementary
Table 3.
For the Control of Eating Questionnaire,
the domains craving control (weeks 26
and 52) and craving for savory (week 52)
were significantly improved in favor of
oral semaglutide versus empagliflozin
(treatment policy estimand). Both do-
mains were significantly in favor of oral
semaglutide at both weeks 26 and 52 for
the trial product estimand. Patient-
reported outcomes are summarized in
Supplementary Fig. 7.
Safety
The overall number of adverse events
and proportion of patients reporting
adverse events were similar with oral
semaglutide and empagliflozin, and
most events were mild to moderate
severity (Table 3). Fewer patients expe-
rienced serious adverse events in the
oral semaglutide group. There was
one death in the empagliflozin group
(undetermined cause). The most frequent





Patients, n 411 410 821
Age (years), mean (SD) 57 (10) 58 (10) 58 (10)
Female, n (%) 205 (49.9) 201 (49.0) 406 (49.5)
Race, n (%)
White 355 (86.4) 353 (86.1) 708 (86.2)
Black or African American 26 (6.3) 33 (8.0) 59 (7.2)
Asian 28 (6.8) 21 (5.1) 49 (6.0)
Other 2 (0.5) 3 (0.7) 5 (0.6)
Ethnicity, n (%)
Hispanic or Latino 91 (22.1) 108 (26.3) 199 (24.2)
Durationofdiabetes (years),mean (SD) 7.2 (5.8) 7.7 (6.3) 7.4 (6.1)
Body weight (kg), mean (SD) 91.9 (20.5) 91.3 (20.1) 91.6 (20.3)
BMI (kg/m2), mean (SD) 32.9 (6.3) 32.8 (5.9) 32.8 (6.1)
HbA1c, mean (SD)
% 8.1 (0.9) 8.1 (0.9) 8.1 (0.9)
mmol/mol 65 (10) 65 (10) 65 (10)
Fasting plasma glucose, mean (SD)
mmol/L 9.5 (2.3) 9.7 (2.5) 9.6 (2.4)
mg/dL 171.5 (41.8) 174.0 (45.2) 172.8 (43.5)
Estimated glomerular filtration rate*
(mL/min/1.73 m2), mean (SD) 96 (15) 95 (15) 95 (15)
*Glomerular filtration rate was estimated by the Chronic Kidney Disease Epidemiology
Collaboration equation.
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adverse event with oral semaglutide was
nausea, which was nonserious, usually
mild to moderate severity and transient,
and did not exceed a prevalence of 10%
at any time (Table 3 and Supplementary
Fig. 8). Female and male genital mycotic
infections of mild to moderate severity
occurred more frequently with empagli-
flozin than with oral semaglutide (8.5%
and 6.7% vs. 2.0% and 0%, respectively)
(Supplementary Table 4).
Adverse events resulting in trial prod-
uct discontinuation were more frequent
with oral semaglutide than with empagli-
flozin (10.7% vs. 4.4%) andwere primarily
related to gastrointestinal symptoms
(8.0% vs. 0.7%) (Table 3). In both groups,
premature discontinuations mainly oc-
curred in the first 16 weeks of treatment.
Incidence of severe or confirmed symp-
tomatic hypoglycemic episodes (,56mg/dL
[,3.1 mmol/L]) was low and similar in
bothgroups (Table 3). Diabetic retinopathy–
related adverse events were reported
in 14 (3.4%) patients in the oral sema-
glutide group and in 5 (1.2%) in the
empagliflozin group (in-trial period)
(Supplementary Table 5). All such events
were identified by routine eye examina-
tion as part of the trial protocol and were
nonserious, of mild or moderate severity,
and did not require treatment. EAC-
confirmed malignant neoplasms were
identified in seven (1.7%) patients in
the oral semaglutide group and two
(0.5%) in the empagliflozin group (in-trial
period). There was no clustering of malig-
nancies in any particular organ or system
(Supplementary Table 6). Cardiovascular
events occurred at a similar rate in both
groups (EAC confirmed; oral semaglutide
n5 5 [1.2%], empagliflozin n5 6 [1.5%])
(Supplementary Table 6). Other EAC-
confirmed events and safety assess-
ments are reported in Supplementary
Tables 6 and 7.
CONCLUSIONS
Oral semaglutide is the first oral GLP-1RA
to be investigated for the treatment of
type 2 diabetes. In PIONEER 2, oral sem-
aglutide was superior to empagliflozin,
with meaningful reductions in HbA1c at
26 weeks in patients with type 2 diabetes
uncontrolled on metformin monotherapy.
Furthermore, the difference between treat-
ments remained significant at 52 weeks.
Figure 1—Glycemic control and body weight–related efficacy end points. A: Observed absolute change in HbA1c over time. B: Estimated changes from
baseline in HbA1c at weeks 26 and 52. C: Observed proportions of patients achieving HbA1c ,7% (53 mmol/mol) at weeks 26 and 52. D: Observed
absolute change in bodyweight over time. E: Estimated changes from baseline in bodyweight at weeks 26 and 52. F: Observed proportions of patients
achievingbodyweight reduction$5%atweeks26and52. Treatmentpolicy estimand:Data irrespectiveofdiscontinuationof trial productand initiation
of rescuemedicationwere included. Trial product estimand: Data collected after discontinuation of trial product or initiation of rescuemedication are
excluded. P values are two-sided and unadjusted. *Superiority confirmed for oral semaglutide versus empagliflozin. Observed mean change (6 SEM)
from baseline (A and D), estimatedmean changes from baseline at week 26 and 52 (B and E), and observed proportions of patients achieving target at
weeks 26 and 52 (C and F). Patient numbers represent patients contributing to the means. EOR, estimated odds ratio.
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Attainment of ADA-recommended HbA1c
targets at 26 and 52 weeks was also
significantly greater with oral semaglu-
tide. Reductions in fasting plasma glucose
were similar in both groups, suggesting
differences in glycemic control may be
mostly driven by the greater reduction in
postprandial glucose with oral semaglutide.
Reductions in body weight occurred
with both treatments, but superiority
of oral semaglutide versus empagliflozin
could not be confirmed at week 26.
However, weight loss in the empagliflozin
group stabilized aroundweek 26, whereas
in the oral semaglutide group, weight
loss continued until around week 38
and was significantly greater at 52 weeks
on the basis of the trial product estimand.
This significantly greater weight loss at
52 weeks with oral semaglutide on the
basis of the trial product estimand reflects
the treatment effect without the con-
founding influence of rescue medication
use and treatment discontinuations. Pa-
tients discontinuing oral semaglutide
could not be switched to additional anti-
diabetic medication with a comparable
weight-reducing effect, while patients
on empagliflozin could be switched to
GLP-1RAs.
The safety profile of oral semaglutide
was consistent with previous trials
(11–16). More patients prematurely
discontinued treatment because of
adverse events with oral semaglutide
versus empagliflozin mainly as a result
of gastrointestinal symptoms associated
with dose escalation. The proportion of
adverse events leading to discontinuation
of oral semaglutide (10.7%) was similar
to previous observations with injectable
GLP-1RAs (6–11%) (4,33,34).
The use of subcutaneous semaglutide
has previously been associated with a
higher rate of diabetic retinopathy–
related complications compared with
placebo, which is consistent with the
phenomenon of early worsening of pre-
existing diabetic retinopathy secondary
to an initial, rapid improvement in glyce-
mic control (6,35). The possible effect of
subcutaneous semaglutide on diabetic
eye disease is being further investigated
in the ongoing FOCUS trial (NCT03811561)
(36). In the current trial, diabetic retinopathy–
related adverse events were more
frequentwith oral semaglutide compared
with empagliflozin, although occurrence
was low in both groups (3.4%vs. 1.2%).All
events were nonserious, most were mild
in severity, and none required treat-
ment or led to trial product discontinu-
ation. All were discovered during routine
Figure 1—Continued
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end-of-treatment eye examination and
were diagnosed as nonproliferative dia-
betic retinopathy. In a longer-term,
78-week, double-blind trial, no im-
balance in the occurrence of diabetic
retinopathy–related events was observed
between oral semaglutide 3, 7, and 14 mg
and sitagliptin (6.7%, 6.0%, 5.6%, and
7.7%, respectively) (15). Occurrence of
diabetic retinopathy–related events was
also similar with oral semaglutide and
placebo (7.1% vs. 6.3%) in a double-blind
trial that assessed cardiovascular out-
comes in patients at high cardiovascular
risk (17).
This trial provides a comparison of two
increasingly used drug classes that are
commonly added to metformin when
glycemic control is not achieved. The
principal limitation of the trial was the
open-label design.
In conclusion, theoralGLP-1 analogoral
semaglutide was superior to the SGLT-2
inhibitor empagliflozin for reduction in
HbA1c, but not body weight, at 26 weeks
in patients with type 2 diabetes uncon-
trolled with metformin. Reductions in
HbA1c were significantly greater with
oral semaglutide at 52 weeks. Assessed
by the trial product estimand, oral
semaglutide provided significant reductions
in body weight at 52 weeks. Oral sema-
glutide was well tolerated, with a safety
profile consistent with that of GLP-1RAs.
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Table 3—On-treatment adverse events
Patients, n (%)




Adverse events 289 (70.5) 283 (69.2)
Serious adverse events 27 (6.6) 37 (9.0)
Adverse event severity
Mild 242 (59.0) 240 (58.7)
Moderate 140 (34.1) 118 (28.9)
Severe 24 (5.9) 23 (5.6)
Severe or blood glucose–confirmed
symptomatic hypoglycemic episode*†‡ 7 (1.7) 8 (2.0)
ADA-classified hypoglycemic episode* 45 (11.0) 39 (9.5)
Severe hypoglycemic episode*† 1 (0.2) 1 (0.2)
Most frequent adverse events $5% in
either group (preferred term)
Nausea 81 (19.8) 10 (2.4)
Diarrhea 38 (9.3) 13 (3.2)
Vomiting 30 (7.3) 7 (1.7)
Decreased appetite 21 (5.1) 2 (0.5)
Influenza 8 (2.0) 21 (5.1)
Adverse events resulting in premature trial
drug discontinuation 44 (10.7) 18 (4.4)
Adverse events resulting in premature
trial drug discontinuation (.1% for
any system organ class or preferred
term)
Gastrointestinal disorders 33 (8.0) 3 (0.7)
Nausea 21 (5.1) 2 (0.5)
Vomiting 11 (2.7) 1 (0.2)
Abdominal pain 5 (1.2) 0
Infections and infestations 0 5 (1.2)
Deaths 0 1 (0.2)§
Safety end points were assessed using the safety analysis set (all patients exposed to one or more
doses of trial product) and evaluated for both the on-treatment period (while on trial product) and
the in-trial period (while in trial, regardless of discontinuation of trial product or use of rescue
medication). *Hypoglycemic episodeswere reportedon a separate form fromadverseevents.†An
episode that is severe, according to theADAclassification (requires assistanceof anotherperson to
actively administer carbohydrate, glucagon, or other corrective action) (29). ‡Blood glucose
confirmation of symptomatic hypoglycemia was based on a blood glucose value,56mg/dL, with
symptoms consistent with hypoglycemia. §One patient in the empagliflozin group died as a result
of undetermined reasons after 268 days on trial drug.
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19. Häring HU, Merker L, Seewaldt-Becker E,
et al.; EMPA-REG METSU Trial Investigators.
Empagliflozin as add-on to metformin plus
sulfonylurea in patients with type 2 diabetes:
a 24-week, randomized, double-blind, placebo-
controlled trial. Diabetes Care 2013;36:3396–
3404
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